Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 29/11/2020
SIETES contiene 93175 citas

 
 
 1 a 20 de 695 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho L-P, Clark T, Djukanovic R, Wilkinson TMA, on behalf of the Inhaled Interferon Beta COVID-19 Study Group. . The Lancet Respiratory Medicine 0:1. [Ref.ID 103778]
2.Enlace a cita original Cita con resumen
WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv 2020:15 de octubre. [Ref.ID 103745]
3. Cita con resumen
4. Cita con resumen
5. Cita con resumen
Branswell H. WHO to launch multinational trial to jumpstart search for coronavirus drugs. STAT 2020:18 de marzo. [Ref.ID 103558]
6. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
7. Cita con resumen
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, for the OPERA I and OPERA II Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017;376:221-34. [Ref.ID 101375]
8.Enlace a cita original
Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ 2016;354:i3518. [Ref.ID 100715]
9. Cita con resumen
Anónimo. Experimental MS drug works better than rival, clinical trial suggests. DIA Daily 2016:5. [Ref.ID 100667]
10.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
11. Cita con resumen
Anónimo. Drugs for multiple sclerosis. Med Lett Drugs Ther 2016;58:71-4. [Ref.ID 100455]
13. Cita con resumen
Anónimo. Daclatasvir. Prescrire 2015;35:738-9. [Ref.ID 99846]
14. Cita con resumen
Anónimo. Lédipasvir + sofosbuvir. Prescrire 2015;35:732-8. [Ref.ID 99845]
15.Enlace a cita original Cita con resumen
Anónimo. Abordaje de la hepatitis C. ¿Tiempos para la esperanza?. Boletín de Información Farmacoterapéutica de Navarra 2015;23:1-10. [Ref.ID 99823]
16. Cita con resumen
Anónimo. Experimental drug successful in treating both forms of MS, clinical trials show. DIA Daily 2015:9 de octubre. [Ref.ID 99557]
17. Cita con resumen
Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, Farley MM. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015;61:1304-6. [Ref.ID 99556]
18. Cita con resumen
Anónimo. Peginterferon beta-1a (Plegridy) for multiple sclerosis. Med Lett Drugs Ther 2015;57:67-9. [Ref.ID 99450]
19. Cita con resumen
Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407-19. [Ref.ID 98960]
20. Cita con resumen
Anónimo. Siméprévir. Prescrire 2015;35:94-5. [Ref.ID 98910]
Seleccionar todas
 
 1 a 20 de 695 siguiente >>